|1.||Coiffier, Bertrand: 48 articles (09/2015 - 01/2002)|
|2.||Salles, Gilles: 45 articles (11/2015 - 01/2002)|
|3.||Friedberg, Jonathan W: 44 articles (10/2015 - 06/2002)|
|4.||Czuczman, Myron S: 43 articles (12/2015 - 02/2002)|
|5.||Byrd, John C: 37 articles (01/2015 - 02/2002)|
|6.||Gascoyne, Randy D: 35 articles (09/2015 - 08/2005)|
|7.||Witzig, Thomas E: 35 articles (09/2015 - 01/2002)|
|8.||O'Brien, Susan: 34 articles (06/2015 - 02/2002)|
|9.||Keating, Michael J: 33 articles (11/2015 - 02/2002)|
|10.||Emery, Paul: 32 articles (01/2016 - 06/2004)|
01/01/2015 - "Rituximab as a single agent is highly effective and tolerable in first-line treatment of primary MALT Ocular adnexal Lymphomas. "
01/01/2015 - "Additionally, prophylaxis was dramatically effective in preventing PCP in rituximab-received lymphoma patients, suggesting that rituximab should be recommended for these patients. "
07/01/2010 - "In conclusion, immunochemotherapy treatment dramatically improved the outcome of patients with nodal DLBCL; however, its effect was less in primary extranodal cases, so the prognosis of patients with nodal and extranodal lymphomas has been equalized in the rituximab era."
06/01/2010 - "However, the maintenance therapy in aggressive lymphomas most probably gives no further improvement in patients, who have received rituximab already in the induction treatment. "
10/01/2009 - "Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized. "
|2.||Non-Hodgkin Lymphoma (Lymphosarcoma)
04/01/2012 - "AIMS Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphoma (NHL). "
04/01/2006 - "CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. "
12/01/2004 - "The anti-CD20 antibody rituximab is useful in the treatment of certain B-cell malignancies, most notably non-Hodgkin's lymphoma. "
04/01/2004 - "Most experience is available for anti-CD20 (rituximab) which led to a significant improvement of the outcome in B-cell non-Hodgkin's lymphoma (NHL). "
02/01/2003 - "In summary, rituximab appears highly active as first-line single-agent therapy for indolent non-Hodgkin's lymphoma and responses may be improved with maintenance courses of rituximab. "
|3.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
08/01/2005 - "Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia."
08/01/2015 - "Despite the improvement in overall survival in patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era, the occurrence of central nervous system (CNS) relapse heralds a very poor prognosis. "
10/01/2012 - "We retrospectively reviewed the medical records of 160 patients with diffuse large B-cell lymphoma (DLBCL) in complete remission (CR) following first-line treatment with rituximab-containing therapy. "
08/01/2012 - "Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. "
09/01/2011 - "When rituximab (R) was added to this regimen, the prognosis of diffuse large B-cell lymphoma (DLBCL) was markedly improved. "
|4.||B-Cell Lymphoma (Lymphoma, B Cell)
08/01/2013 - "The introduction of rituximab, an anti-CD20 monoclonal antibody, has dramatically improved the treatment outcomes of patients with B cell lymphoma. "
07/15/2012 - "The use of IFRT in patients with primary mediastinal B-cell lymphoma who achieved complete response remain as the best treatment available, even in patients that received rituximab during induction."
01/01/2010 - "Because of the excellent results achieved with PA therapy, the potential role of rituximab (an anti-CD20 monoclonal antibody that is highly effective against most B-cell lymphomas) in HCL has yet to be elucidated. "
02/24/2011 - "Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B-cell lymphomas. "
03/01/2010 - "Despite its excellent safety and efficacy profile, only a small portion of B-cell lymphoma patients treated with rituximab as a single agent have sustained complete remissions. "
|5.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
07/10/2011 - "Rituximab maintenance (RM) therapy following successful induction has recently emerged as a highly effective treatment for follicular lymphoma (FL). "
09/01/2006 - "Most commonly studied in patients with follicular lymphoma, the monoclonal antibody rituximab has not only improved the response rate and progression-free survival for both treatment-naive and relapsed/refractory patients, it is also beginning to demonstrate an improvement in overall survival. "
03/01/2006 - "Rituximab maintenance therapy following successful induction has emerged as a highly effective treatment for follicular lymphoma. "
03/01/2015 - "Rituximab was approved in France in 2004, following randomized trials that demonstrated efficacy in newly diagnosed high tumour burden follicular lymphoma (FL). "
10/01/2014 - "The prognosis of follicular lymphoma (FL) has significantly improved over the last decade, particularly following the introduction of the anti-CD20 monoclonal antibody rituximab, which has challenged the old concept of FL as an incurable disease. "
|10.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation